The balance between two immune signaling molecules — CXCL13 and BAFF — may help identify the hard-to-treat inflammation in the brain and spinal cord that’s thought to be a major driver of disability progression in multiple sclerosis (MS), a study found. The findings may help identify which patients are most likely to benefit from BTK…
Category: Multiple Sclerosis Research
FDA approves generic injection to help manage MS
The U.S. Food and Drug Administration (FDA) has approved Scinopharm Taiwan’s glatiramer acetate injection, a generic of Copaxone, to treat multiple sclerosis (MS). Scinopharm is the first pharmaceutical company in Taiwan to win U.S. approval for glatiramer acetate, marking a significant milestone for the country in the global industry, according to a company press release….
Generic fingolimod is it inferior?
Tweet Yesterday I did a post on Tysabri and Tyruko and we had a few posts saying the biosimilar was not the same. Some have taken to the media to aire this view, but there have been many other me-toos been introduced to the MS word. So what do you think about this? We have…
Toward a Global Research Plan for Preventing Multiple Sclerosis
The post Toward a Global Research Plan for Preventing Multiple Sclerosis appeared first on MS Australia. Source: www.msaustralia.org.au
Happy 2026, or how time flies when MS is stealing time
You see, in my head, my resolutions have already borne plenty of success. In reality, crippling fatigue and facial nerve pain have halted even more tasks, projects and mighty dreams, but, LGO*. Source: irelandms.com
Natalizumab now recommended in England to treat hard-to-control MS
The National Institute for Health and Care Excellence (NICE) in England is recommending natalizumab — sold as Tysabri and Tyruko — as an option for certain people with hard-to-control multiple sclerosis (MS). NICE is responsible for deciding which medicines will be covered by the National Health Service (NHS) in England, with decisions also influencing NHS…
Mothers with MS symptoms may face longer waits for a diagnosis, study finds
Women with multiple sclerosis (MS) who have children experience significantly longer waits before receiving a diagnosis than women without children, according to a new U.S. study. On average, each child was associated with an additional 1.28-year delay in diagnosis. The delay was even longer among women whose symptoms began during their reproductive years and among…
Metformin trial failure?
Tweet Metformin has become flavour of the month trial and there are numerous studies ongoing or recently completed. Here they have done a study of metformin plus beta interferon and say that there was no evident benefit….Should we fear for Octopus the MS trial in UK and Australia looking at metformin? However, here they split…
International experts chart global strategy to prevent multiple sclerosis
The post International experts chart global strategy to prevent multiple sclerosis appeared first on MS Australia. Source: www.msaustralia.org.au
Foralumab nasal spray continues to show long-term safety in SPMS: Data
Tiziana Life Sciences‘ intranasal spray foralumab continues to be safe and well-tolerated, with no drug-related serious side effects reported after long-term use, according to an annual report filed with the U.S. Food and Drug Administration (FDA). The company is developing foralumab for neuroinflammatory diseases such as multiple sclerosis (MS), Alzheimer’s disease, and multiple system atrophy….